Sarepta settles REGENXBIO, UPenn patent litigation for USD 39 million
SRPT•Settlement resolves AAVrh74 patent litigation
Sarepta Therapeutics reached a settlement on Sept. 23, 2026 to resolve patent infringement litigation tied to AAVrh74-based gene therapies.
- Payment of USD 39 million due to REGENXBIO within 10 days; charge previously recorded for the quarter ended June 30, 2026.
- REGENXBIO and the University of Pennsylvania released claims through the effective date tied to certain AAVrh74-related patents.
- Non-suit commitments cover ELEVIDYS and other AAVrh74-based programs; REGENXBIO also agreed not to sue over patents covering existing ELEVIDYS.
- Cases to be dismissed with prejudice; no admission of liability; each party to cover its own legal costs.
